16/04/2018 14:17:17

Novo Nordisk A/S - Share repurchase programme

Related content
15 Oct - 
Novo Nordisk A/S - Share repurchase programme
08 Oct - 
Novo Nordisk A/S - Share repurchase programme
01 Oct - 
Novo Nordisk A/S - Share repurchase programme
Related debate
15 Oct - 
Den var god - også alpehuens med originalerne, se..
15 Oct - 
Det behøver originaler ikke, de kan selv.
15 Oct - 
😊 Lige et øjeblik - alpe og tommy skal lige hav..

Bagsværd, Denmark, 16 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.

Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018.

Further information

Media:

 

 

Anne Margrethe Hauge +45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US) +1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 
Peter Hugreffe Ankersen +45 3075 9085

phak@novonordisk.com

Anders Mikkelsen +45 3079 4461

armk@novonordisk.com

Christina Kjær +45 3079 3009

cnje@novonordisk.com

Company Announcement No 32 / 2018

CA20180416 Safe Harbour CA_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Oct
NOVO-B
Nordnet er største sælger i Novo nu (hvor vi måske burde købe) og fonde og store investorer køber   ..
7
11 Oct
NOVO-B
du kan lade være med at sidde og glo på handelsloggen. Da størstedelen af handlerne er anonymiserede..
6
11 Oct
NOVO-B
Aktimarkedet er IKKE en børnehave, hvor du - som i det meste af resten af samfundet - holdes i hånde..
4
11 Oct
NOVO-B
Aktionærerne skal være klar til at købe !  Aktierne bliver jo shortet for at få private til at sælge..
4
15 Oct
NOVO-B
Måske hér et resultat af de nye ADA & EASD anbefalinger til at vælge Victocta/Ozempic før insulin. ?..
3
10 Oct
NOVO-B
@gittekh Det er helt korrekt, naar du og leksikon skriver, at frigoerelse (eller injektion) af insul..
3
15 Oct
NOVO-B
Regnskabet kommer ikke til at skuffe, det er mere fremtiden jeg er bekymret for, og det er det den h..
2
11 Oct
NOVO-B
Vent med køb af Novo til kurs 220 😉🤛🏿
2
11 Oct
NOVO-B
Jeg shorter ikke, men sagen er vel bare, at manskal holde sig fra at gå ind i ting man ikke forstår...
2
11 Oct
NOVO-B
Shortgribbene har travlt, meget travlt, her til morgen med hhv 81 - 98% af alt køb og 80 - 98% af al..
2

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
2
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
3
JCDecaux: Update on JCDecaux's proposed acquisition of APN Outdoor in Australia
4
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
5
ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)

Related stock quotes

Novo Nordisk B A/S 273.05 -0.1% Stock price decreasing
Novo Nordisk 41.36 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 October 2018 01:09:27
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB1 - 2018-10-16 02:09:27 - 2018-10-16 01:09:27 - 1000 - Website: OKAY